The times they are a-changin: Carbapenems for extended- spectrum-β-lactamase-producing bacteria

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5095-5096

  Rodríguez Baño, Jesús ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; CEFMETAZOLE; CEFOXITIN; CEFTRIAXONE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; FLOMOXEF; FOSFOMYCIN; LATAMOXEF; TEMOCILLIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA LACTAMASE INHIBITOR;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL INFECTION; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; HEALTHCARE ASSOCIATED INFECTION; HUMAN; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DRUG EFFECTS; ENTEROBACTERIACEAE; ENZYMOLOGY; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CARBAPENEMS; CEPHAMYCINS; ENTEROBACTERIACEAE; MICROBIAL SENSITIVITY TESTS;

EID: 84940920411     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01333-15     Document Type: Review

References (15)

1. Rossolini GM, D'Andrea MM, Mugnaioli C. 2008. The spread of CTX-Mtype extended-spectrum beta-lactamases. Clin Microbiol Infect 14(Suppl 1): S33-S41. http://dx.doi.org/10.1111/j.1469-0691.2007.01867.x.
2. Paterson DL, Bonomo RA. 2005. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 18:657-686. http://dx.doi.org/10 .1128/CMR.18.4.657-686.2005.
3. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, Laxminarayan R. 2014. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 14: 742-750. http://dx.doi.org/10.1016/S1473-3099(14)70780-7.
4. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 17:1791-1798. http://dx .doi.org/10.3201/eid1710.110655.
5. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, Di-Persio J. 2010. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 54:3031-3034. http://dx.doi.org/10.1128/AAC.01808-09.
6. Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á, Extended-Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. 2012. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54:167-174. http://dx.doi.org/10.1093/cid/cir790.
7. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE, Antibacterial Resistance Leadership Group. 2015. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis 60:1319-1325. http://dx.doi.org/10.1093/cid /civ003.
8. th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, 25 to 28 April 2015.
9. Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S, Stewardson AJ, Rogers BA, McBryde ES, Roberts JA, Lipman J, Athan E, Paul SK, Baker P, Harris-Brown T, Paterson DL. 2015. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials 16:24. http://dx.doi.org/10.1186/s13063-014-0541-9.
10. Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, Shimizu T, Watanabe H, Doi S, Tanaka M, Takakura S, Ichiyama S. 2015. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother 59:5107-5113. http://dx.doi .org/10.1128/AAC.00701-15.
11. Soubirou JF, Rossi B, Couffignal C, Ruppé E, Chau F, Massias L, Lepeule R, Mentre F, Fantin B. 2015. Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15. J Antimicrob Chemother 70:1466-1472. http://dx.doi.org/10.1093/jac/dku542.
12. Balakrishnan I, Awad-El-Kariem FM, Aali A, Kumari P, Mulla R, Tan B, Brudney D, Ladenheim D, Ghazy A, Khan I, Virgincar N, Iyer S, Carryn S, Van de Velde S. 2011. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 66:2628-2631. http://dx .doi.org/10.1093/jac/dkr317.
13. Rodríguez-Baño J, Picón E, Navarro MD, López-Cerero MD, Pascual and the ESBL-REIPI Group. 2012. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli. Clin Microbiol Infect 18:894-900. http://dx.doi.org/10.1111/j.1469-0691.2011 .03673.x.
14. Livermore DM, Andrews JM, Hawkey PM, Ho PL, Keness Y, Doi Y, Paterson D, Woodford N. 2012. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 67:1569-1577. http://dx.doi.org/10.1093/jac/dks088.
15. Rosso-Fernández C, Sojo-Dorado J, Barriga A, Lavín-Alconero L, Palacios Z, López-Hernández I, Merino V, Camean M, Pascual A, Rodríguez-Baño J, FOREST Study Group. 2015. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open 5:e007363. http://dx.doi.org/10.1136/bmjopen-2014-007363.